Your browser doesn't support javascript.
loading
One-Stop Shop: 18F-Flortaucipir PET Differentiates Amyloid-Positive and -Negative Forms of Neurodegenerative Diseases.
Hammes, Jochen; Bischof, Gérard N; Bohn, Karl P; Onur, Özgür; Schneider, Anja; Fliessbach, Klaus; Hönig, Merle C; Jessen, Frank; Neumaier, Bernd; Drzezga, Alexander; van Eimeren, Thilo.
Afiliação
  • Hammes J; Multimodal Neuroimaging, Department of Nuclear Medicine, University Hospital and Medical Faculty, University of Cologne, Cologne, Germany jochen.hammes@uk-koeln.de.
  • Bischof GN; Radiologische Allianz, Hamburg, Germany.
  • Bohn KP; Multimodal Neuroimaging, Department of Nuclear Medicine, University Hospital and Medical Faculty, University of Cologne, Cologne, Germany.
  • Onur Ö; Faculty of Mathematics and Natural Sciences, University of Cologne, Cologne, Germany.
  • Schneider A; Multimodal Neuroimaging, Department of Nuclear Medicine, University Hospital and Medical Faculty, University of Cologne, Cologne, Germany.
  • Fliessbach K; Department of Nuclear Medicine, Inselspital University Hospital, University of Bern, Bern, Switzerland.
  • Hönig MC; Department of Neurology, University Hospital and Medical Faculty, University of Cologne, Cologne, Germany.
  • Jessen F; Cognitive Neuroscience (INM-3), Institute of Neuroscience and Medicine, Research Center Jülich, Jülich, Germany.
  • Neumaier B; German Center for Neurodegenerative Diseases, Bonn and Cologne, Germany.
  • Drzezga A; Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, University of Bonn, Bonn, Germany.
  • van Eimeren T; German Center for Neurodegenerative Diseases, Bonn and Cologne, Germany.
J Nucl Med ; 62(2): 240-246, 2021 02.
Article em En | MEDLINE | ID: mdl-32620704
ABSTRACT
Tau protein aggregations are a hallmark of amyloid-associated Alzheimer disease and some forms of non-amyloid-associated frontotemporal lobar degeneration. In recent years, several tracers for in vivo tau imaging have been under evaluation. This study investigated the ability of 18F-flortaucipir PET not only to assess tau positivity but also to differentiate between amyloid-positive and -negative forms of neurodegeneration on the basis of different 18F-flortaucipir PET signatures.

Methods:

The 18F-flortaucipir PET data of 35 patients with amyloid-positive neurodegeneration, 19 patients with amyloid-negative neurodegeneration, and 17 healthy controls were included in a data-driven scaled subprofile model (SSM)/principal-component analysis (PCA) identifying spatial covariance patterns. SSM/PCA pattern expression strengths were tested for their ability to predict amyloid status in a receiver-operating-characteristic analysis and validated with a leave-one-out approach.

Results:

Pattern expression strengths predicted amyloid status with a sensitivity of 0.94 and a specificity of 0.83. A support vector machine classification based on pattern expression strengths in 2 different SSM/PCA components yielded a prediction accuracy of 98%. Anatomically, prediction performance was driven by parietooccipital gray matter in amyloid-positive patients versus predominant white matter binding in amyloid-negative patients.

Conclusion:

SSM/PCA-derived binding patterns of 18F-flortaucipir differentiate between amyloid-positive and -negative neurodegenerative diseases with high accuracy. 18F-flortaucipir PET alone may convey additional information equivalent to that from amyloid PET. Together with a perfusion-weighted early-phase acquisition (18F-FDG PET-equivalent), a single scan potentially contains comprehensive information on amyloid (A), tau (T), and neurodegeneration (N) status as required by recent biomarker classification algorithms (A/T/N).
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carbolinas / Doenças Neurodegenerativas / Tomografia por Emissão de Pósitrons / Amiloide Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carbolinas / Doenças Neurodegenerativas / Tomografia por Emissão de Pósitrons / Amiloide Idioma: En Ano de publicação: 2021 Tipo de documento: Article